Abstract 2071P
Background
The objective of this study is to identify the major issues and concerns of cancer patients in Korea related to cancer, anti-cancer therapy, and patient care that are mentioned on social media.
Methods
We collected data from open-access forums, blogs, and social networking sites using professional ISO 20252 certified online access tools. We searched the terms “cancer”, "cancer treatment", and “patient care” and collected social media posts between October 2021 and September 2022, excluding spam and advertisements.
Results
Total 169,575 social media posts were collected. Among the posts, 51% were related to cancer symptoms, concerns following diagnosis, and cancer etiology, while 39% discussed treatment methods, treatment-related side effects, novel therapies, as well as costs. The remaining posts centered on how to manage in daily life. The most frequently mentioned cancer types were breast, lung, colorectal, stomach, and liver cancer, consistent with common cancers in Korea. Concerning the difficulties experienced, 52% reported physical challenges, 42% reported emotional challenges, and 6% discussed daily life issues, such as diet and sexual relationships. Additionally, patients had high expectations for immune checkpoint inhibitors. Patients tend to view clinical trial participation as an alternative when conventional treatments are ineffective and see it positively as a way to participate without financial burden. However, some express safety concerns. Patients frequently shared tips for managing daily life on social media, such as healthy eating, taking supplements, and light exercise to maintain physical strength.
Conclusions
Our findings suggest that cancer patients in Korea frequently use social media for information. The high frequency of emotional difficulties mentioned indicates that patients face persistent emotional challenges throughout the cancer journey. This study underscores the potential benefits of analyzing social media posts by cancer patients, providing valuable insights for healthcare professionals and patients. Moreover, it emphasizes the importance of the developing and delivering professional information on daily life management for cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Korean Society of Medical Oncology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06